A multidisciplinary research team has revealed that the circadian clock -- the biological pacemaker that governs daily rhythms in physiological processes, including immune functions -- can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy. Checkpoint inhibitors block different proteins from binding to tumor cells, allowing the immune system's T cells to kill the tumor.